- Home
- OFS vs HLVX Comparison
OFS vs HLVX Comparison
Compare OFS & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- HLVX
- Stock Information
- Founded
- OFS 2001
- HLVX 2020
- Country
- OFS United States
- HLVX United States
- Employees
- OFS N/A
- HLVX N/A
- Industry
- OFS Finance/Investors Services
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- HLVX Health Care
- Exchange
- OFS Nasdaq
- HLVX Nasdaq
- Market Cap
- OFS 120.2M
- HLVX 104.3M
- IPO Year
- OFS 2012
- HLVX 2022
- Fundamental
- Price
- OFS $8.32
- HLVX $2.06
- Analyst Decision
- OFS
- HLVX Hold
- Analyst Count
- OFS 0
- HLVX 1
- Target Price
- OFS N/A
- HLVX $2.00
- AVG Volume (30 Days)
- OFS 35.7K
- HLVX 981.8K
- Earning Date
- OFS 07-31-2025
- HLVX 08-06-2025
- Dividend Yield
- OFS 16.25%
- HLVX N/A
- EPS Growth
- OFS N/A
- HLVX N/A
- EPS
- OFS 0.76
- HLVX N/A
- Revenue
- OFS $43,337,000.00
- HLVX N/A
- Revenue This Year
- OFS N/A
- HLVX N/A
- Revenue Next Year
- OFS N/A
- HLVX N/A
- P/E Ratio
- OFS $10.88
- HLVX N/A
- Revenue Growth
- OFS N/A
- HLVX N/A
- 52 Week Low
- OFS $7.77
- HLVX $1.34
- 52 Week High
- OFS $9.80
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- OFS 47.67
- HLVX 48.76
- Support Level
- OFS $8.18
- HLVX $2.05
- Resistance Level
- OFS $8.37
- HLVX $2.10
- Average True Range (ATR)
- OFS 0.13
- HLVX 0.02
- MACD
- OFS 0.01
- HLVX -0.00
- Stochastic Oscillator
- OFS 42.86
- HLVX 27.27
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.